Zkusit zdarma
Arvinas, Inc.

Arvinas, Inc.

ARVN
Cena:
$ 9.09
-0.01 (-0.11%)
Valuace
100
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Arvinas Employees Give Back During Company-wide Impact Day

Arvinas Employees Give Back During Company-wide Impact Day

10:30 18-05-2026

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage bi...

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

13:54 13-05-2026

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday....

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

15:50 12-05-2026

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript...

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

14:38 12-05-2026

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is enteri...

Arvinas Q1 Earnings Call Highlights

Arvinas Q1 Earnings Call Highlights

10:10 12-05-2026

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensi...

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

9:31 12-05-2026

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Est...

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

7:05 12-05-2026

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeli...

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

7:00 12-05-2026

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for ...

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

7:00 05-05-2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology com...

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

8:05 04-05-2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology...

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

12:43 01-05-2026

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degra...

Arvinas (ARVN) Expected to Announce Earnings on Thursday

Arvinas (ARVN) Expected to Announce Earnings on Thursday

4:04 23-04-2026

Arvinas (NASDAQ: ARVN - Get Free Report) is anticipated to release its Q1 2026 results before the ma...

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN

4:45 08-04-2026

JPMorgan Chase and Co. lifted its holdings in Arvinas, Inc. (NASDAQ: ARVN) by 475.5% in the undefine...

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

3:56 02-04-2026

Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The lat...

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

7:00 11-03-2026

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical...

Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference

Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference

4:21 11-03-2026

Arvinas (NASDAQ: ARVN) executives outlined a portfolio shift toward early-stage development and prev...

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

17:30 10-03-2026

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript...

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

17:37 24-02-2026

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript...

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

10:41 24-02-2026

Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Est...

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

7:00 24-02-2026

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including...

close

ARVINAS ANNOUNCES APPOINTMENT OF RANDY TEEL, PH.D., AS PRESIDENT, CHIEF EXECUTIVE OFFICER, AND DIRECTOR

12-02-2026
– APPOINTMENT OF AN EXPERIENCED ARVINAS EXECUTIVE WITH A PROVEN ABILITY TO DRIVE STRATEGY AND INNO...
Více zde

ARVINAS PRESENTS PRECLINICAL DATA SUPPORTING MECHANISTIC SYNERGIES AND ENHANCED ANTITUMOR ACTIVITY WITH THE COMBINATION OF ARV-393 AND GLOFITAMAB AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION

06-12-2025
– DATA SUPPORT INITIATION OF A COMBINATION COHORT IN THE ONGOING PHASE 1 CLINICAL TRIAL TO EVALUAT...
Více zde

ARVINAS TO PRESENT AT PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

26-11-2025
NEW HAVEN, CONN., NOV. 26, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS ANNOUNCES DATA PRESENTATIONS FROM THE VEPDEGESTRANT (ARV-471) CLINICAL DEVELOPMENT PROGRAM AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

24-11-2025
NEW HAVEN, CONN., NOV. 24, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

05-11-2025
– PRESENTED POSITIVE DATA FROM PHASE 1 CLINICAL TRIALS WITH ARV-102 IN HEALTHY VOLUNTEERS AND PATI...
Více zde

ARVINAS TO PRESENT PRECLINICAL DATA FOR ARV-393 AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

03-11-2025
NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

03-11-2025
NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 5, 2025

29-10-2025
NEW HAVEN, CONN., OCT. 29, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS PRESENTS PRECLINICAL DATA FOR ARV-806 DEMONSTRATING ROBUST AND DIFFERENTIATED ACTIVITY IN MODELS OF KRAS G12D-MUTATED CANCER AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

24-10-2025
– IN VIVO, ARV-806 DEMONSTRATED ROBUST AND DURABLE KRAS G12D DEGRADATION, LEADING TO SIGNIFICANT T...
Více zde

ARVINAS TO PRESENT PRECLINICAL DATA FOR ARV-806, A PROTAC KRAS G12D DEGRADER, AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

22-10-2025
NEW HAVEN, CONN., OCT. 22, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

PATIENT-REPORTED OUTCOMES FROM VERITAC-2 CLINICAL TRIAL SUPPORT CLINICAL BENEFIT OF VEPDEGESTRANT IN PATIENTS WITH ESR1-MUTATED, ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE-BASED THERAPY

20-10-2025
– DATA DEMONSTRATED THAT VEPDEGESTRANT MAINTAINED PATIENTS' QUALITY OF LIFE FOR STATISTICALLY SIGN...
Více zde

ARVINAS TO PRESENT DATA FROM THE VEPDEGESTRANT CLINICAL DEVELOPMENT PROGRAM AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS

13-10-2025
– PRESENTATION TO INCLUDE NEW PATIENT-REPORTED OUTCOMES (PRO) DATA FROM THE PHASE 3 VERITAC-2 CLIN...
Více zde

ARVINAS PRESENTS LATE BREAKING, POSITIVE PHASE 1 CLINICAL DATA FOR ARV-102, A PROTAC LRRK2 DEGRADER, AT THE 2025 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS®

05-10-2025
– ARV-102 WAS WELL TOLERATED IN CLINICAL TRIALS FOR BOTH HEALTHY VOLUNTEERS AND PATIENTS WITH PARK...
Více zde

ARVINAS TO PRESENT CLINICAL DATA FOR ARV-102, A PROTAC LRRK2 DEGRADER, AT THE 2025 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS®

01-10-2025
NEW HAVEN, CONN., OCT. 01, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS PROVIDES UPDATE ON COLLABORATION WITH PFIZER AND ANNOUNCES FURTHER ACTIONS TO SUPPORT VALUE CREATION

17-09-2025
ARVINAS AND PFIZER PLAN TO JOINTLY SELECT THIRD PARTY FOR THE OUT-LICENSING AND COMMERCIALIZATION OF...
Více zde

ARVINAS ANNOUNCES FDA ACCEPTANCE OF THE NEW DRUG APPLICATION FOR VEPDEGESTRANT FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED BREAST CANCER

08-08-2025
– FILING BASED ON PIVOTAL PHASE 3 VERITAC-2 CLINICAL TRIAL DEMONSTRATING STATISTICALLY SIGNIFICANT...
Více zde

ARVINAS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

06-08-2025
– SUBMITTED NEW DRUG APPLICATION FOR VEPDEGESTRANT FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED ...
Více zde

ARVINAS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

30-07-2025
NEW HAVEN, CONN., JULY 30, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE B...
Více zde

ARVINAS ANNOUNCES RETIREMENT OF CHIEF EXECUTIVE OFFICER AND SUCCESSION PLAN

09-07-2025
– JOHN HOUSTON, PH.D., CHAIRPERSON, CEO AND PRESIDENT AT ARVINAS, ANNOUNCES PLANS TO RETIRE AS CEO...
Více zde

ARVINAS PRESENTS PRECLINICAL DATA FOR PROTAC BCL6 DEGRADER, ARV-393, AT THE EUROPEAN HEMATOLOGY ASSOCIATION 2025 CONGRESS

13-06-2025
– ARV-393 DEMONSTRATED SIGNIFICANT SINGLE-AGENT ACTIVITY IN MODELS OF NODAL T-FOLLICULAR HELPER CE...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

07-06-2025
NEW YORK , JUNE 7, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

06-06-2025
NEW YORK, JUNE 06, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

ARVINAS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA FOR VEPDEGESTRANT FOR PATIENTS WITH ESR1-MUTATED ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER

06-06-2025
– THIS SUBMISSION IS SUPPORTED BY THE PIVOTAL PHASE 3 VERITAC-2 CLINICAL TRIAL, RESULTS OF WHICH W...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

05-06-2025
NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 5, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF...
Více zde

ARVINAS TO PRESENT PRECLINICAL DATA FOR PROTAC BCL6 DEGRADER, ARV-393, AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING

05-06-2025
– COMPANY TO SHOWCASE PRECLINICAL STUDIES OF ARV-393, AN INVESTIGATIONAL ORAL PROTAC BCL6 DEGRADER...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

04-06-2025
NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 4, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

02-06-2025
NEW YORK, JUNE 02, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARVINAS, INC. - ARVN

01-06-2025
NEW YORK , JUNE 1, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

ARVINAS AND PFIZER'S VEPDEGESTRANT SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH ESR1-MUTANT, ER+/HER2- ADVANCED BREAST CANCER

31-05-2025
NEW HAVEN, CONN. AND NEW YORK, MAY 31, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN) AND PFI...
Více zde

ARVINAS TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

30-05-2025
NEW HAVEN, CONN., MAY 30, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BI...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-12 00:00:008-KStáhnout
2025-12-08 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-10-24 01:00:008-KStáhnout
2025-10-24 00:00:008-KStáhnout
2025-10-20 01:00:008-KStáhnout
2025-10-20 00:00:008-KStáhnout
2025-10-06 01:00:008-KStáhnout
2025-10-06 00:00:008-KStáhnout
2025-09-17 01:00:008-KStáhnout
2025-09-17 00:00:008-KStáhnout
2025-08-08 01:00:008-KStáhnout
2025-08-08 00:00:008-KStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-07-09 01:00:008-KStáhnout
2025-07-09 00:00:008-KStáhnout
2025-06-30 01:00:008-KStáhnout
2025-06-30 00:00:008-KStáhnout
2025-06-13 01:00:008-KStáhnout
2025-06-13 00:00:008-KStáhnout
2025-06-06 01:00:008-KStáhnout
2025-06-06 00:00:008-KStáhnout
2025-06-02 01:00:008-KStáhnout
2025-06-02 00:00:008-KStáhnout
2025-05-01 01:00:008-KStáhnout
2025-05-01 01:00:0010-QStáhnout
2025-05-01 00:00:008-KStáhnout
2025-05-01 00:00:0010-QStáhnout
2025-04-28 01:00:008-KStáhnout
2025-04-28 00:00:008-KStáhnout
2025-04-04 01:00:008-KStáhnout
2025-04-04 00:00:008-KStáhnout
2025-03-11 00:00:008-KStáhnout
2025-03-10 23:00:008-KStáhnout
2025-02-11 00:00:008-KStáhnout
2025-02-11 00:00:0010-KStáhnout
2025-02-10 23:00:008-KStáhnout
2025-02-10 23:00:0010-KStáhnout
2025-01-22 00:00:008-KStáhnout
2025-01-21 23:00:008-KStáhnout
2025-01-10 00:00:008-KStáhnout
2025-01-09 23:00:008-KStáhnout
2025-01-06 00:00:008-KStáhnout
2025-01-05 23:00:008-KStáhnout
2024-12-16 00:00:008-KStáhnout
2024-12-15 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-11-19 00:00:008-KStáhnout
2024-11-18 23:00:008-KStáhnout
2024-10-30 00:00:008-KStáhnout
2024-10-30 00:00:0010-QStáhnout
2024-10-29 23:00:008-KStáhnout
2024-10-29 23:00:0010-QStáhnout
2024-08-20 01:00:008-KStáhnout
2024-08-20 00:00:008-KStáhnout
2024-07-30 01:00:008-KStáhnout
2024-07-30 01:00:0010-QStáhnout
2024-07-30 00:00:008-KStáhnout
2024-07-30 00:00:0010-QStáhnout
2024-06-24 01:00:008-KStáhnout
2024-06-24 00:00:008-KStáhnout
2024-06-18 01:00:008-KStáhnout
2024-06-18 00:00:008-KStáhnout
2024-06-17 01:00:008-KStáhnout
2024-06-17 00:00:008-KStáhnout
2024-05-30 01:00:008-KStáhnout
2024-05-30 00:00:008-KStáhnout
2024-05-16 01:00:008-KStáhnout
2024-05-16 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-04-11 01:00:008-KStáhnout
2024-04-11 00:00:008-KStáhnout
2024-03-18 00:00:008-KStáhnout
2024-03-17 23:00:008-KStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-02-20 00:00:008-KStáhnout
2024-02-19 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-12-06 00:00:008-KStáhnout
2023-12-05 23:00:008-KStáhnout
2023-11-27 00:00:008-KStáhnout
2023-11-26 23:00:008-KStáhnout
2023-11-07 00:00:008-KStáhnout
2023-11-07 00:00:0010-QStáhnout
2023-11-06 23:00:008-KStáhnout
2023-11-06 23:00:0010-QStáhnout
2023-10-23 01:00:008-KStáhnout
2023-10-23 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-21 01:00:008-KStáhnout
2023-06-21 00:00:008-KStáhnout
2023-06-08 01:00:008-KStáhnout
2023-06-08 00:00:008-KStáhnout
2023-05-05 01:00:008-KStáhnout
2023-05-05 01:00:0010-QStáhnout
2023-05-05 00:00:008-KStáhnout
2023-05-05 00:00:0010-QStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2023-02-23 00:00:008-KStáhnout
2023-02-23 00:00:0010-KStáhnout
2023-02-22 23:00:008-KStáhnout
2023-02-22 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-16 00:00:008-KStáhnout
2022-12-15 23:00:008-KStáhnout
2022-12-08 00:00:008-KStáhnout
2022-12-07 23:00:008-KStáhnout
2022-11-22 00:00:008-KStáhnout
2022-11-21 23:00:008-KStáhnout
2022-11-09 00:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:008-KStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-08-19 01:00:008-KStáhnout
2022-08-19 00:00:008-KStáhnout
2022-08-05 01:00:008-KStáhnout
2022-08-05 00:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-06-21 01:00:008-KStáhnout
2022-06-21 00:00:008-KStáhnout
2022-06-09 01:00:008-KStáhnout
2022-06-09 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2022-02-17 00:00:008-KStáhnout
2022-02-16 23:00:008-KStáhnout
2022-02-15 00:00:008-KStáhnout
2022-02-14 23:00:008-KStáhnout
2021-12-10 00:00:008-KStáhnout
2021-12-09 23:00:008-KStáhnout
2021-11-03 00:00:008-KStáhnout
2021-11-03 00:00:0010-QStáhnout
2021-11-02 23:00:008-KStáhnout
2021-11-02 23:00:0010-QStáhnout
2021-09-28 01:00:008-KStáhnout
2021-09-28 00:00:008-KStáhnout
2021-09-13 01:00:008-KStáhnout
2021-09-13 00:00:008-KStáhnout
2021-08-06 01:00:008-KStáhnout
2021-08-06 00:00:008-KStáhnout
2021-08-05 01:00:008-KStáhnout
2021-08-05 01:00:0010-QStáhnout
2021-08-05 00:00:008-KStáhnout
2021-08-05 00:00:0010-QStáhnout
2021-07-22 01:00:008-KStáhnout
2021-07-22 00:00:008-KStáhnout
2021-06-09 01:00:008-KStáhnout
2021-06-09 00:00:008-KStáhnout
2021-05-04 01:00:008-KStáhnout
2021-05-04 01:00:0010-QStáhnout
2021-05-04 00:00:008-KStáhnout
2021-05-04 00:00:0010-QStáhnout
2021-03-01 00:00:008-KStáhnout
2021-03-01 00:00:0010-KStáhnout
2021-02-28 23:00:008-KStáhnout
2021-02-28 23:00:0010-KStáhnout
2021-01-06 00:00:008-KStáhnout
2021-01-05 23:00:008-KStáhnout
2020-12-18 00:00:008-KStáhnout
2020-12-17 23:00:008-KStáhnout
2020-12-14 00:00:008-KStáhnout
2020-12-13 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-10-14 01:00:008-KStáhnout
2020-10-14 00:00:008-KStáhnout
2020-08-04 01:00:008-KStáhnout
2020-08-04 01:00:0010-QStáhnout
2020-08-04 00:00:008-KStáhnout
2020-08-04 00:00:0010-QStáhnout
2020-06-30 01:00:008-KStáhnout
2020-06-30 00:00:008-KStáhnout
2020-06-11 01:00:008-KStáhnout
2020-06-11 00:00:008-KStáhnout
2020-06-05 01:00:008-KStáhnout
2020-06-05 00:00:008-KStáhnout
2020-06-04 01:00:008-KStáhnout
2020-06-04 00:00:008-KStáhnout
2020-05-29 01:00:008-KStáhnout
2020-05-29 00:00:008-KStáhnout
2020-05-14 01:00:008-KStáhnout
2020-05-14 00:00:008-KStáhnout
2020-04-28 01:00:008-KStáhnout
2020-04-28 01:00:0010-QStáhnout
2020-04-28 00:00:008-KStáhnout
2020-04-28 00:00:0010-QStáhnout
2020-03-16 00:00:008-KStáhnout
2020-03-16 00:00:0010-KStáhnout
2020-03-15 23:00:008-KStáhnout
2020-03-15 23:00:0010-KStáhnout
2020-02-06 00:00:008-KStáhnout
2020-02-05 23:00:008-KStáhnout
2019-11-21 00:00:008-KStáhnout
2019-11-20 23:00:008-KStáhnout
2019-11-12 00:00:008-KStáhnout
2019-11-11 23:00:008-KStáhnout
2019-11-04 00:00:008-KStáhnout
2019-11-04 00:00:0010-QStáhnout
2019-11-03 23:00:008-KStáhnout
2019-11-03 23:00:0010-QStáhnout
2019-10-23 01:00:008-KStáhnout
2019-10-23 00:00:008-KStáhnout
2019-08-05 01:00:008-KStáhnout
2019-08-05 01:00:0010-QStáhnout
2019-08-05 00:00:008-KStáhnout
2019-08-05 00:00:0010-QStáhnout
2019-07-25 01:00:008-KStáhnout
2019-07-25 00:00:008-KStáhnout
2019-07-16 01:00:008-KStáhnout
2019-07-16 00:00:008-KStáhnout
2019-06-04 01:00:008-KStáhnout
2019-06-04 00:00:008-KStáhnout
2019-05-28 01:00:008-KStáhnout
2019-05-28 00:00:008-KStáhnout
2019-05-09 01:00:0010-QStáhnout
2019-05-09 00:00:0010-QStáhnout
2019-05-08 01:00:008-KStáhnout
2019-05-08 00:00:008-KStáhnout
2019-04-01 01:00:008-KStáhnout
2019-04-01 00:00:008-KStáhnout
2019-03-26 00:00:0010-KStáhnout
2019-03-25 23:00:0010-KStáhnout
2019-03-15 00:00:008-KStáhnout
2019-03-14 23:00:008-KStáhnout
2018-11-14 00:00:0010-QStáhnout
2018-11-13 23:00:0010-QStáhnout
2018-10-01 01:00:008-KStáhnout
2018-10-01 00:00:008-KStáhnout
preloader